Eli Lilly agreed to acquire Verve Therapeutics for about $1 billion upfront, adding a potential treatment for cardiovascular disease to its portfolio. Under the agreement, the pharmaceutical company will buy all of the gene-editing startup’s shares outstanding for $10.

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment portfolio.

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of experimental cardiac health drugs.